UCB Shares Reach Fresh Record After Rival MoonLake’s Trial Data

UCB SA shares surged to a record high after analysts said late-stage clinical trial data from rival MoonLake Immunotherapeutics showed UCB’s skin disorder medicine is superior. MoonLake lost most of its value in premarket trading....

Redirecting to full article...